News >

FDA Approves Entrectinib for NTRK+ Tumors and ROS1+ NSCLC

Gina Columbus @ginacolumbusonc
Published: Thursday, Aug 15, 2019

The FDA has granted an accelerated approval to entrectinib (Rozlytrek) for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor an NTRK fusion, and has also approved the agent for the treatment of adults with ROS1-positive, metastatic non–small cell lung cancer (NSCLC).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication